Clinical Trials Logo

Corneal Ulcer clinical trials

View clinical trials related to Corneal Ulcer.

Filter by:

NCT ID: NCT06331910 Not yet recruiting - Clinical trials for Neurotrophic Keratopathy

Efficacy and Safety of Topical Insulin for Neurotrophic Corneal Ulcers

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

To evaluate Safety and efficacy of topical insulin in treatment of neurotrophic corneal ulcers

NCT ID: NCT05940376 Not yet recruiting - Diabetes Mellitus Clinical Trials

Topical Insulin in Neurotrophic Keratopathy After Diabetic Vitrectomy

Start date: July 15, 2023
Phase:
Study type: Observational

Various treatment options have been proposed in managing NK such as preservative-free lubrication (PF-L), withdrawal of epitheliotoxic medication, prophylactic antibiotics, applying of bandage contact lenses, using hemoderivatives 8, topical insulin, recombinant nerve growth factor (rNGF) or epidermal growth factor (rEGF).11,12, amniotic membrane transplant (AMT), or corneal neurotization.2,4,9,10 Topical insulin has been reported to effectively promote the healing of persistent corneal epithelial defects. In our retrospective study, we explored the safety and efficacy of topical insulin, as a first-line treatment, in treatment-naïve acute NK after diabetic vitrectomy.

NCT ID: NCT05924893 Completed - Cornea Ulcer Clinical Trials

The Use of Naltrexone Hydrochloride to Promote Healing in Patients With Resistant Non-infectious Corneal Ulcer

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The opioid growth factor-receptor antagonist-naltrexone hydrochloride (NTX)- has gained much reach interest for applications in ophthalmology, because of its novel mechanism of action for speeding up corneal wound healing in both diabetics and non-diabetics, effective both locally and systemically and its availability as a low molecular weight synthetic drug.

NCT ID: NCT05891106 Completed - Corneal Ulcer Clinical Trials

AONDA Therapeutic Indication Study I

Start date: June 28, 2023
Phase:
Study type: Observational

This study will be used to support assessment of AIR OPTIX® NIGHT & DAY® AQUA (AONDA) Soft Contact Lenses' safety and performance in accordance with updated European Union Medical Device Regulation (EU MDR) requirements.

NCT ID: NCT05809245 Terminated - Clinical trials for Neurotrophic Keratitis

Corneal Neurotization as a Treatment for Neurotrophic Keratopathy

Start date: March 15, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the efficacy of sural nerve transfer and cadaveric nerve graft to re-establish corneal sensation in patients with neurotrophic keratopathy.

NCT ID: NCT05705024 Recruiting - Corneal Ulcer Clinical Trials

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

Start date: September 29, 2023
Phase: Phase 2
Study type: Interventional

The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0334). In the present study, we want to study the efficacy of this treatment on chronic epitheliopathies.

NCT ID: NCT05515731 Completed - Cornea Ulcer Clinical Trials

Platelet Rich Plasma as a Treatment For Resistant Corneal Ulcers

Start date: January 1, 2021
Phase: Phase 4
Study type: Interventional

This prospective study involved 14 patients aged > 18 years with RCUs not responding to conventional treatment. All patients were treated with E-PRP drops (one drop), preservative-free artificial tears, antibiotic eye drop four times daily and systemic vitamin A once daily for one month. All patients were examined at 1, 2, 4, 6 and 8 weeks after the treatment initiation. In each visit, the following parameters were assessed: best corrected visual acuity (BCVA), anterior segment, corneal healing, condition of the conjunctiva, presence of abnormal discharge and symptoms reported.

NCT ID: NCT05313828 Recruiting - Corneal Ulcer Clinical Trials

Effect of Various Treatment Modalities on Dendritic Vial Ulcer

Start date: March 18, 2022
Phase:
Study type: Observational

Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldwide . HSK is defined as a corneal inflammatory condition caused by the HSV infection . The global incidence of herpetic keratitis is estimated at 1.5 million per year, resulting in 40,000 new cases of severe visual impairment associated with corneal scarring and opacification . HSV type I (HSV-1) is by far the most predominant causative pathogen of eye infections]. HSV-1 is also known for causing orolabial herpes, HSV folliculitis, herpes gladiatorum, herpetic whitlow, and eczema herpeticum . HSV can be transferred to the eye by touching an active lesion and then the eye. The National Health and Nutrition Evaluation revealed a seroprevalence of HSV-1 in 53.9% of 14-49 year olds, and 90% of adults 50 years or older , indicating that the majority of the population has been exposed to this virus thus are at risk of developing HSK. In this study we evaluate the efficacy of different treatment modalities on viral keratitis HSK.

NCT ID: NCT05268718 Recruiting - Clinical trials for Keratitis, Ulcerative

Au-Ag-Cu2O NG With PTT Anti Drug-resistant Microbial Keratitis

Start date: August 1, 2021
Phase: Early Phase 1
Study type: Interventional

This clinical study was conducted to evaluate the efficacy and safety of gold-silver cuprous oxide composite nanogels combined with photothermal therapy system in the treatment of severe drug-resistant bacterial keratitis ineffective by traditional antibiotic treatment in human eyes, and to provide translational applications. Based on the clinical evidence, a more effective and safe innovative treatment plan for corneal diseases has been developed.

NCT ID: NCT05255107 Recruiting - Keratitis Clinical Trials

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers

Start date: March 14, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of previously untreated corneal ulcers. The PXL Platinum 330 System is a combination product consisting of an ultraviolet A (UV-A) 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Riboflavin 0.23% PESCHKE-L Solution) administered in conjunction with the UV-A light as a photosensitizer. The PXL Platinum 330 System is intended to induce corneal collagen CXL to improve the biomechanical properties of the cornea by strengthening the corneal tissue in the anterior stroma. Corneal collagen CXL is performed by pretreating the cornea with riboflavin ophthalmic solution beginning 40 min before UV-A light exposure to saturate the corneal tissue with the riboflavin photosensitizer. The cornea is then irradiated with UV-A light (365 nm) at an irradiance of 18 mW/cm2 (5 seconds on, 5 seconds off) for 10 min. Exposure of the cornea to this UV-A light regimen after topical administration of riboflavin ophthalmic solution has been shown to induce CXL of the corneal collagen fibrils, with a resultant increase in tensile strength and diameter of the collagen fibrils. Clinically, CXL has been shown to stabilize the corneal curvature in eyes with progressive keratoconus, with no significant change in the refractive index of the cornea. Numerous reports and a few clinical trials have also shown benefit in aiding resolution of infective corneal ulcers.